Literature DB >> 9917651

Osteonecrosis of the femoral head. Potential treatment with growth and differentiation factors.

M A Mont1, L C Jones, T A Einhorn, D S Hungerford, A H Reddi.   

Abstract

Basic and clinical research have shown the efficacy of various cellular mediators (bone morphogenetic proteins, interleukins, angiogenic growth factors) in healing bone defects. The potential application of these growth and differentiation factors to other musculoskeletal conditions, including osteonecrosis of the femoral head, only recently has been explored. Osteonecrosis is a disease of unknown pathogenesis that usually progresses to hip joint destruction necessitating total hip arthroplasty. The pathology involves ischemic events followed by death of bone and marrow elements. A process of repair then is initiated, but unless the lesion is small (less than 15% of the femoral head involved), this repair process is usually ineffective. The net result is weakening of subchondral bone with subsequent collapse of the articular surface. Because the results of hip arthroplasty in patients with osteonecrosis are relatively poor, much focus has been on modalities aimed at femoral head preservation. The surgical alternatives may include core decompression, osteotomy, nonvascularized, and vascularized bone grafting, which might be enhanced with the use of growth and differentiation factors. At least three of these factors are potential candidates as therapeutic modalities: cytokines (such as interleukins, tumor necrosis factors, and signaling molecules such as fibroblast growth factors, platelet derived growth factors, insulinlike growth factors, and transforming growth factor betas), bone morphogenetic proteins, and angiogenic factors. Despite considerable effort, evaluation of these growth and differentiation factors has been hampered by the lack of an animal model that adequately simulates the pathology of osteonecrosis in humans. Therefore, investigators have attempted to model certain aspects of the disease process. Recently, several investigators have attempted to mimic osteonecrosis in the femoral head of large mammals by combinations of devascularization, freezing, osteotomy of the femoral neck, or creation of a head defect. Results from some of these studies have confirmed the potential for growth and differentiation factors to effect more rapid healing and filling of defects with biomechanically competent and viable bone. The application of this therapy shows promise, and clinical studies on efficacy and safety are ongoing.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9917651

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  51 in total

1.  [Growth and differentiation factor 5 (GDF-5) composite improves the healing of necrosis of the femoral head in a sheep model. Analysis of an animal model].

Authors:  H-G Simank; F Herold; M Schneider; U Maedler; R Ries; C Sergi
Journal:  Orthopade       Date:  2004-01       Impact factor: 1.087

2.  The use of an injectable calcium sulphate/calcium phosphate bioceramic in the treatment of osteonecrosis of the femoral head.

Authors:  Roberto Civinini; Pietro De Biase; Christian Carulli; Fabrizio Matassi; Lorenzo Nistri; Rodolfo Capanna; Massimo Innocenti
Journal:  Int Orthop       Date:  2012-03-17       Impact factor: 3.075

3.  A kind of specific osteolytic destruction of the vertebral bodies.

Authors:  Baogan Peng; Jinhong Chen; Xiaodong Pang; Yan Hei
Journal:  BMJ Case Rep       Date:  2012-06-05

4.  Core decompression and osteonecrosis intervention rod in osteonecrosis of the femoral head: clinical outcome and finite element analysis.

Authors:  Thilo Floerkemeier; André Lutz; Udo Nackenhorst; Fritz Thorey; Hazibullah Waizy; Henning Windhagen; Gabriela von Lewinski
Journal:  Int Orthop       Date:  2010-10-24       Impact factor: 3.075

5.  CORR® ORS Richard A. Brand Award: Disruption in Peroxisome Proliferator-Activated Receptor-γ (PPARG) Increases Osteonecrosis Risk Through Genetic Variance and Pharmacologic Modulation.

Authors:  Cody C Wyles; Christopher R Paradise; Matthew T Houdek; Susan L Slager; Andre Terzic; Atta Behfar; Andre J van Wijnen; Rafael J Sierra
Journal:  Clin Orthop Relat Res       Date:  2019-08       Impact factor: 4.176

6.  NCI, NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: endocrine challenges-thyroid dysfunction, growth impairment, bone health, & reproductive risks.

Authors:  Christopher C Dvorak; Clarisa R Gracia; Jean E Sanders; Edward Y Cheng; K Scott Baker; Michael A Pulsipher; Anna Petryk
Journal:  Biol Blood Marrow Transplant       Date:  2011-10-17       Impact factor: 5.742

7.  A new osteonecrosis animal model of the femoral head induced by microwave heating and repaired with tissue engineered bone.

Authors:  Yanlin Li; Rui Han; Chengkui Geng; Yongnian Wang; Lei Wei
Journal:  Int Orthop       Date:  2008-10-28       Impact factor: 3.075

8.  Treatment of experimental osteonecrosis of the hip in adult rabbits with a single local injection of recombinant human FGF-2 microspheres.

Authors:  Yutaka Kuroda; Haruhiko Akiyama; Keiichi Kawanabe; Yasuhiko Tabata; Takashi Nakamura
Journal:  J Bone Miner Metab       Date:  2010-03-31       Impact factor: 2.626

Review 9.  Available Findings Fail to Provide Strong Evidence of the Role of Bone Morphogenic Protein-2 in Femoral Head Osteonecrosis.

Authors:  Ali Parsa; Hamed Vahedi; Karan Goswami; Arash Aalirezaie
Journal:  Arch Bone Jt Surg       Date:  2020-01

Review 10.  [Pain management in non-juvenile, aseptic osteonecrosis].

Authors:  M Jäger; A Werner; S Lentrodt; U Mödder; R Krauspe
Journal:  Schmerz       Date:  2004-12       Impact factor: 1.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.